Recent

% | $
Quotes you view appear here for quick access.

Pharmacyclics, Inc. Message Board

  • jgmtruth jgmtruth May 3, 2013 12:09 PM Flag

    Drug Manufacturers and the FDA Collaborate More Closely for Faster Drug Approval: An Exclusive Interview with an Expert Equity Analyst Reveals Some Top Stock Picks in This Vital Industry

    67 WALL STREET, New York - May 3, 2013 - The Wall Street Transcript has just published its Biotechnology and Pharmaceuticals Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.
    Topics covered: Health Care - Biotechnology and Pharmaceuticals - Executive Officer Interviews - Biotechnology and Pharmaceutical Investing - Orphan Drug and Biologics Manufacturing - Biotechnology and Pharmaceutical Companies Valuation
    Companies include: Medicines Co. (MDCO), Cubist Pharmaceuticals Inc. (CBST), Regeneron Pharmaceuticals Inc. (REGN), Seattle Genetics Inc. (SGEN), Immunogen Inc. (IMGN), Merck & Co. Inc. (MRK), Pharmacyclics Inc. (PCYC), Johnson & Johnson (JNJ), Gilead Sciences Inc. (GILD), Infinity Pharmaceuticals, Inc. (INFI), Celgene Corporation (CELG), Amgen Inc. (AMGN), Biogen Idec Inc. (BIIB) and many more.
    Sorry can't full article.

    Sentiment: Strong Buy

 
PCYC
257.100.00(0.00%)Apr 23 3:59 PMEDT